Podcasts about poised

In this week's episode of Poised for Exit, we sit down with Jacob Petersen, a board-certified M&A intermediary who breaks down what really makes a business attractive to buyers.Jacob shares his journey from accounting to business brokerage and explains how he helps privately held business owners understand and increase the value of their companies.The conversation explores key valuation concepts like Seller's Discretionary Earnings (SDE) and EBITDA, with Jacob explaining how each is used and what they reveal about a company's true cash flow. He also clears up common misconceptions about intangible assets and why strong documentation is essential.Jacob highlights the importance of clean financials, realistic forecasting, and reducing owner dependency. He shares real-life success stories, including one where a business with minimal hard assets sold for over 2.5 million thanks to strong systems and diverse customers.If you are a business owner thinking about selling or just want to increase your company's value, this episode offers practical advice and powerful takeaways to help you build a more sellable business.Find Jacob hereConnect with Julie Keyes, Keyestrategies LLCFounder, Consultant, Author, Pod-caster and Instructor

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to announce a pivotal distribution agreement with Z.T. Distribution, a leading consumer packaged goods distributor serving over 1,000 retail outlets across Wisconsin, Minnesota, and Illinois. The agreement grants Z.T. exclusive distribution rights for Nevis' flagship hemp-derived THC beverage, Happy Apple™, in Wisconsin and select territories in Minnesota and Illinois. Kueber emphasized that Z.T. Distribution's century-long history and extensive retail network will allow Nevis Brands to significantly accelerate its market penetration in the Midwest. The partnership is expected to bring Happy Apple™ to major grocery chains, independent retailers, and convenience stores, tapping into growing consumer demand for functional and cannabis-infused beverages. The announcement coincides with Nevis Brands' second fiscal quarter results, which showed continued quarter-over-quarter revenue growth. Kueber attributed this to stable performance in its licensed cannabis markets and the early success of its hemp-derived THC beverage portfolio. The company posted a 75% gross profit margin—unchanged from Q1—highlighting the strength of its capital-light licensing model that allows for strong margins with minimal overhead. Looking ahead, Kueber said Nevis is well-positioned for further growth as consumer adoption of cannabis beverages increases. The company's flagship brands, Major™ and Happy Apple™, will be central to its national expansion strategy, with additional distribution deals currently under negotiation. Cost control and EBITDA optimization remain top priorities for the company. With audit-related costs now behind them, Nevis expects improved profitability in the second half of the year as it enhances efficiencies across its licensing, legal, and compliance frameworks. #proactiveinvestors #nevisbrandsinc #cse #nevi #otcqb #nevif #majorbrand #cannabis #CannabisInvesting #THCDrinks #HappyApple #CannabisStocks #HempTHC #CannabisBeverages #InvestorUpdate #JohnKueber #CannabisNews #CannabisRevenue #DebtReduction #ProactiveInvestors

Jordan Blashek says the defense sector is on the cusp of a decade-long bull run, driven by a "revolution in military affairs." He cites the rise of small, autonomous systems and the increasing importance of A.I. and energy as key trends. Blashek highlights companies like AeroVironment (AVAV), Tesla (TSLA) and Meta Platforms (META) as potential winners in this space, and notes that the government's $70 billion investment in A.I. and energy is a major signal of the sector's criticality to U.S. national security.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Send us a textThe New York Giants have a loaded roster heading into 2025, and it's time to break down the biggest breakout candidates who could reshape the future of Big Blue. From first-round edge rusher Abdul Carter to RB1-in-waiting Tyrone Tracy Jr., Drew and Rob dive deep into every name you need to know ahead of camp. The Athletic picked Carter as the Giants' breakout player. NFL Media named Tracy to the 2025 All-Breakout Team. Tyler Nubin is stepping into a massive leadership role. Darius Alexander might be the rookie surprise of the year. Are these just flashes or the start of something major?The guys also debate the controversial 2016 NFL Draft redraft, where PFF swaps out Eli Apple for DeForest Buckner — but should the pick have been Chris Jones, Derrick Henry, or even Joe Thuney? What does the history of that class say about the Giants' past scouting? They react to Abdul Carter declaring “I ain't no rookie,” and whether his confidence will translate into on-field dominance.You'll also get the latest buzz on Chase Edmonds' bold claim that the Giants might have the best defensive line in football, what ESPN said about Andrew Thomas slipping in tackle rankings, and whether Russell Wilson could actually hurt Tyrone Tracy Jr.'s production.This episode is packed with insights, reactions, and fiery takes — so buckle up.

Sia Nejad, Larry Hartstein, and Claudia Bellofatto give ALL their best bets and predictions for the 2025 New York Jets! They have Breece Hall bets, win total predictions, playoff picks, and MORE! #SportsBetting #Gambling #Betting #JustinFields #breecehall #newyorkjets #newyorkfootball #NewYorkJetsBets #NFLBets #NFLFutures #nflbetting

These 13 Dividend Aristocrats have all stumbled yet they all continue to raise their dividends year after year. Each of these Dividend Aristocrats appears to be undervalued today and poised for a comeback with an attractive long-term future return.Full Dividend Aristocrat Report: quality-at-a-fair-price.kit.com/aristocratsQuality At A Fair Price: https://qualityatafairprice.substack.com/Patreon: https://www.patreon.com/LongacresFinanceDisclaimer: This video is intended for entertainment purposes only and should not be taken as investment advice.#dividendincome #dividends #dividendgrowthinvesting

The Ohio State Buckeyes lost 14 players to the NFL Draft in April, leaving a lot of spots available for young players to take on much bigger roles in the 2025 Buckeye football season. Tony Gerdeman of BuckeyeHuddle.com thinks there are five Ohio State players poised for a breakout season this fall. He joins host Tom Orr to discuss why WR Brandon Inniss, RB James Peoples, QB Julian Sayin, DE Kenyatta Jackson, Jr, and DT Eddrick Houston could be on the verge of very big things.

Poised to jet off to the 2025 World Cup of Foosball in Spain, RJ delights with his experiences and observations at the 1st Annual North American Multitable Foosball Tournament in Trois Rivières, Quebec, including scary stories about crossing the border these days. KJ lets us hear about a short movie from his daughter Lucy that will go to Cannes, and PJ talks (okay complains) about translation apps. We wander by tidbits about Japanese recycling ideas and favourite viewing choices like Mr. Inbetween, and share whatever fragments our memories hold about Formula 1 racing we may have seen and heard. Or was it the Molson Indy? All in all, we start out with no particular destination and get there in fine style, as usual. Get on board? Links: Shed Dogs; How Brief; Variety's withering review of Never Ending Story III; “Travellers Who Do Not ‘Align' with US Policies Risk Denial of Entry”; the Molson Indy; should travellers use translation apps?; Mr. Inbetween; seeds in Japan's Mainichi newspaper; plastic recycling in BC.

0:00 - Good deal for York and Flyers?11:20 - York must have a power play role26:15 - How much can Rick Tocchet help York?33:40 - We take a look at your comments!

A collaboration between Aston University in the UK and RAD Global will help small farmers in East Africa keep food fresher for longer, preventing food waste and improving livelihoods. Working with other partners they have developed pioneering cold storage boxes which can keep food fresh without access to grid electricity. Affordable cold boxes for small farmers in East Africa Whilst working in Uganda, Tim Messeder, founder of UK agricultural development company RAD Global, noticed that small scale fishers in Uganda had a major problem keeping fish fresh. The African country is large, and this causes an issue in keeping fish fresh in the blistering heat after it is caught from Lake Victoria and from various fishponds spread around the country in remote locations. The fishers, many of whom are women, have to transport their catch for up to nine hours during which time their harvest goes off. Surveys across the region reveal that 42% of traders experience fish spoilage due to inadequate cooling, resulting in lost income and increased food insecurity. To help prevent waste Tim drew up a plan for a cool box that could keep fish fresh for up to 48 hours, could be transported on the back of a motorcycle and was affordable to people on very low incomes. He contacted Aston University and between the two they developed his idea into the prototype now known as RADiCool, which aims to extend the safe selling window for fish from 12 to 24 hours. The prototype development was supported by the Efficiency for Access Research and Development Fund. The RADiCool system features a lightweight, insulated cold box powered by advanced phase change material (PCM) and integrated internet of things (IoT) technology for real-time temperature and GPS monitoring. The innovative system cools fish from 25°C to refrigeration temperatures within four hours and maintains cold storage conditions for over 24 hours, without additional pre-cooling capacity. Purpose-built to fit on motorbikes - the primary transport mode for rural vendors - RADiCool is practical, scalable, and tailored to first and last mile delivery needs in resource-constrained settings. PCM technology is an environmentally friendly solution for maintaining cooling temperatures. The materials absorb and release energy as they transition from solid to liquid and back again, similar to the process of ice melting and refreezing. These specially designed PCMs can maintain a consistent cold temperature for extended periods without the need for continuous electricity. This makes them particularly suitable for transporting food, medicine, and other temperature-sensitive items in an energy-efficient way. The PCM panels for RADiCool are frozen in solar-powered hubs for later use in precooling and storing the fish at the desired temperature. Tim Messeder said: "RADiCool brings together cutting-edge technology while taking into account the challenging realities of the African context. "We are committed to empowering small-scale traders with sustainable solutions that reduce waste and improve livelihoods." The project's success marks a major step forward in addressing the cold chain gap in Africa's informal food markets. Through field testing and technical iteration, the team has developed a system that can function effectively off-grid, supporting food security and economic resilience in the face of climate and infrastructure challenges. RAD Global and Aston University are now focusing on scaling and commercialisation. Planned next steps include finalising the new special design PCM panels, partnering with manufacturers, expanding field trials, and deploying a pay-per-use business model to increase accessibility. Ongoing collaboration with other partners (ThinkAqua UK, Therma-Inova UK and Dulotrop Uganda) will ensure further staff training, impact evaluation, and long-term sustainability. "RADiCool demonstrates the power of cross-sector innovation in addressing global development challenges," said Dr Ahm...

In this week's episode of the Coin Stories News Block powered exclusively by Gemini, we cover these major headlines related to Bitcoin, macroeconomics, and global finance: Trump's Massive Spending Bill Signed Trump Pressures Powell to Cut Rates BlackRock's Bitcoin ETF Drives More Revenue Than its S&P 500 Fund Strategy Becomes Eligible for S&P 500 Inclusion ---- Read every story in the News Block with visuals and charts! Join our mailing list and subscribe to our free Bitcoin newsletter: thenewsblock.substack.com ---- References mentioned in the episode: Trump's Big Bill Puts U.S. on a Perilous Fiscal Path Trump Calls for Powell to “Resign Immediately”  Director Pulte Urges Congress to Investigate Powell Pulte Criticizes Powell for Not Cutting Interest Rates Luke Gromen Tweets on the U.S. Fiscal Situation President Trump's “Fiscal Dominance” Play  Trump Says Cutting Rates Will Save on Costs Bessent Says He Will Issue on the Short End  Ray Dalio's Tweet on the Impact of the Spending Bill Deutsche Bank to Launch Digital Asset Custody Services  BlackRock's IBIT Drives More Revenue Than S&P 500 Fund Eric Balchunas Highlights BlackRock's IBIT Revenues Troy Cross Shares Nakamoto Project's Survey Results  MARA Now Holds More Than 50,000 Bitcoin  Strategy to Join Wall Street Elite After $14 Billion Windfall Strategy Becomes Eligible for S&P 500 Inclusion  Ric Edelman Recommends 10% to 40% Crypto Allocation ---- Natalie's Bitcoin Product and Event Links: Earn 2-4% back in Bitcoin on all your purchases with the orange Gemini Bitcoin credit card: https://www.gemini.com/natalie   Secure your Bitcoin with collaborative custody and set up your inheritance plan with Casa: https://www.casa.io/natalie  Block's Bitkey Cold Storage Wallet was named to TIME's prestigious Best Inventions of 2024 in the category of Privacy & Security. Get 20% off using code STORIES at https://bitkey.world   Master your Bitcoin self-custody with 1-on-1 help and gain peace of mind with the help of The Bitcoin Way: https://www.thebitcoinway.com/natalie  For easy, low-cost, instant Bitcoin payments, I use Speed Lightning Wallet. Get 5000 sats when you download using this link and promo code COINSTORIES10: https://www.speed.app/sweepstakes-promocode/  Bitcoin 2026 will be here before you know it. Get 10% off Early Bird passes using the code HODL: https://tickets.b.tc/event/bitcoin-2026?promoCodeTask=apply&promoCodeInput=  Protect yourself from SIM Swaps that can hack your accounts and steal your Bitcoin. Join America's most secure mobile service, trusted by CEOs, VIPs and top corporations: https://www.efani.com/natalie   Your Bitcoin oasis awaits at Camp Nakamoto: A retreat for Bitcoiners, by Bitcoiners. Code HODL for discounted passes: https://massadoptionbtc.ticketspice.com/camp-nakamoto      ---- This podcast is for educational purposes and should not be construed as official investment advice. ---- VALUE FOR VALUE — SUPPORT NATALIE'S SHOWS Strike ID https://strike.me/coinstoriesnat/ Cash App $CoinStories #money #Bitcoin #investing

4 Stocks Poised to Beat the Market | Trading Tips With Jim (Week of July 7, 2025)Looking for actionable trade ideas and macro insight? In this week's episode, Jim reveals four high-conviction stocks he believes can outpace the broader market, explains why he's still bullish on the Nasdaq's upside potential, and breaks down how Europe's falling energy prices are boosting productivity—a powerful combo that could tame inflation and pave the way for deeper rate cuts.© 2025 StockInvest.us from UAB "Exigam"

5 Teams Poised for a Breakout Season (Including Nebraska)Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this episode of DairyVoice, Connie Kuber of Sealpro Silage Barrier Film by Connor AgriScience and Chris Urban Dairy Management, Inc. talk about an exciting topic. Dairy is perfectly poised at this moment as a health and wellness solution with their nutrient density and being a nutrient powerhouse. Chris discusses DMI's partnerships, new product development and the four areas of health and wellness that are trending. As consumer demand for wellness products grow, they are exploring new ways to incorporate dairy into these conversations.

Hour 3 of JJ & Alex with Jeremiah Jensen and Alex Kirry. Unofficial Big 12 preseason poll NFL Blitz: Which second year QB is poised to continue performing  Best and Worst of the Day

Welcome to another episode of FTN Media's Crossing Routes Podcast, co-hosted by Herms (@herms.bsky.social on Bluesky) and Tyler O (@FFTylerO on X). In this one, the duo discusses a handful of players who disappointed fantasy managers in 2024 that they expect to rebound this season. Which bounceback quarterbacks are Herms and Tyler most excited about? What do they think of Jaylen Waddle now that the Jonnu Smith-Steelers trade has gone down? Listen and find out!Be sure to check out all the incredible fantasy football content at ftnfantasy.com.Tyler O's C.J. Stroud Article: https://ftnfantasy.com/nfl/all-signs-point-to-a-c-j-stroud-bounceback-in-year-3

Dryden Pence discusses the energy landscape ahead of the 4th of July holiday weekend. With tensions in the Middle East easing and OPEC's spare capacity at 5 million barrels a day, Pence believes the risk premium on crude oil has been largely priced in. While he expects a short-term demand spike due to increased travel, Pence doesn't see any major supply disruptions on the horizon. From a sector standpoint, he favors integrated energy companies like ExxonMobil (XOM) and Chevron (CVX), citing their diversified business models, strong downstream margins, and attractive dividend yields.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

The Transfer Show with Dave Davis & Trev Downey brings you the latest Premier League Transfer news update over the last 48 hours, with huge switches in the offing! Learn more about your ad choices. Visit podcastchoices.com/adchoices

AP correspondent Julie Walker reports the New York City elections board is likely to finalize results of mayoral primary today.

Tarik Skubal dominated on Sunday Night Baseball, Cedar Point's new ride has problems and are the Red Wings looking to make a huge splash?

With DIDDY Poised To Win His Case Vs. Cassie - He Picks Up Two New Cases | S*xless Marriage Reality by Greg Adams

The Rebel News podcasts features free audio-only versions of select RebelNews+ content and other Rebel News long-form videos, livestreams, and interviews. Monday to Friday enjoy the audio version of Ezra Levant's daily TV-style show, The Ezra Levant Show, where Ezra gives you his contrarian and conservative take on free speech, politics, and foreign policy through in-depth commentary and interviews. Wednesday evenings you can listen to the audio version of The Gunn Show with Sheila Gunn Reid the Chief Reporter of Rebel News. Sheila brings a western sensibility to Canadian news. With one foot in the oil patch and one foot in agriculture, Sheila challenges mainstream media narratives and stands up for Albertans. If you want to watch the video versions of these podcasts, make sure to begin your free RebelNewsPlus trial by subscribing at http://www.RebelNewsPlus.com

Summary In this episode of Armed American Radio, host Mark Walters discusses the current political climate in New York, the implications for gun rights, and the role of organizations like Patriot Mobile in advocating for the Second Amendment. The conversation highlights the challenges faced by gun owners and the importance of supporting pro-gun businesses. The discussion also touches on the younger generation's understanding of economics and the potential consequences of current political trends. Takeaways The introduction of the show sets the tone for a discussion on gun rights. New York's political landscape is shifting towards more restrictive gun laws. The younger generation lacks understanding of economic principles related to gun ownership. Patriot Mobile plays a significant role in supporting gun rights advocacy. Legislation can have a profound impact on gun ownership and rights. The importance of supporting businesses that align with pro-gun values is emphasized. The conversation highlights the need for awareness among gun owners about political developments. Mark Walters expresses a lack of sympathy for those who vote for restrictive policies. The majority of gun violence is committed with handguns, not rifles. The episode underscores the urgency of protecting Second Amendment rights. Keywords Armed American Radio, gun rights, New York politics, Patriot Mobile, Second Amendment, legislation, freedom, advocacy, conservative voice, NRA  

The fireside chat is a longstanding staple in LUF leadership development and human performance courses.  During a recent weeklong LUF human performance course, Baltimore City Fire Department leaders enjoyed the opportunity to hear Lt Paul Novak Sr. reflect on his career with host Jerry Smith.  Lt Novak joined the ranks of the BCFD in 1973 and retired in 2004.  Lt Novak established himself as one of the department's most experienced, capable, and impactful fire officers.   Paul Sr. was a 2nd generation member of the BCFD, and his sons Paul Jr. and Casey are 3rd generation members.  Lt Novak and members of Engine 13 were featured in the Discovery Channel's 1998 documentary “Streets of Fire.”   

For the 13th consecutive year, the World Economic Forum has released its report on the top ten technologies set to change the world for the better. These technologies will speed our efforts to tackle everything from the energy transition to neurodegenerative diseases and more. Based on expert nominations and rigorous examination, the solutions drive home to leaders the increasing ways that technologies are converging and building on each other and showcase the importance of technology foresight as a key strategic tool to make meaningful change, integration and investment happen. Guests guiding us through this report for the fifth year include Bernie Meyerson, chief innovation officer emeritus at IBM, and Mariette DiChristina, Dean and professor of the practice of journalism at Boston University College of Communication.   This interview was recorded in May 2025 in the New York office of the World Economic Forum. Top 10 Emerging Technologies for this year: - Structural Battery Composites - Collaborative Sensing - Green Nitrogen Fixation - Generative Watermarking - Engineered Living Therapeutics - GLP-1s for Neurodegenerative Diseases - Autonomous Biochemical Sensing - Next-Gen Nuclear Energy - Osmotic Power Systems - Nanozymes About this episode: Top 10 Emerging Technologies Report 2025: These are the top 10 emerging technologies of 2025: Transcript: https://www.weforum.org/podcasts/radio-davos/episodes/top-ten-emerging-tech-2025 Mariette DiChristina, Boston University: Bernie Meyerson: https://www.ibm.com/history/bernard-meyerson Related podcasts: Top 10 Emerging Technologies 2024: Beyond AI: the top-10 tech of 2023 set to change our lives: https://www.weforum.org/podcasts/radio-davos/episodes/top-10-emerging-technologies-2023/

The Mariners crushed the Twins and Cal Raleigh homered again. It's his 32nd homer of the season and the NVP chants have been getting louder. Is it too early to talk MVP? Probably. Is it going to stop us? Probably not. :30- Yesterday we chatted with Curtis Crabtree about JSN following his breakout season last year. What kind of success can we expect from JSN this season without DK Metcalf garnering so much attention? :45- The Thunder are NBA Champions and the talk has already begun about their long-term success potential. Are they built for a dynastic run?

The Mariners crushed the Twins and Cal Raleigh homered again. It's his 32nd homer of the season and the NVP chants have been getting louder. Is it too early to talk MVP? Probably. Is it going to stop us? Probably not. :30- Yesterday we chatted with Curtis Crabtree about JSN following his breakout season last year. What kind of success can we expect from JSN this season without DK Metcalf garnering so much attention? :45- The Thunder are NBA Champions and the talk has already begun about their long-term success potential. Are they built for a dynastic run? See omnystudio.com/listener for privacy information.

The first Test of the Anderson/Tendulkar series is delicately balanced after four days - and that is the best description of the dominant innings of the day by KL Rahul. Perfectly executed, deliciously poised. The Simons assess a lively fourth day and examine the likely outcomes Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

The driver of the No. 13 joins Bringing the Heat.

We start our position-by-position look at the Packers by previewing the running backs and quarterbacks. How do they need to perform to meet expectations this year?GET IN TOUCHLeave us a voicemail and hear yourself in a future episodehttps://www.speakpipe.com/thepowersweepPrefer more old-school contact? Reach out here:https://thepowersweep.com/contactSUPPORT BLUE 58Donate to our Patreon - For as little as $1 per month, you can access Patreon-only content and get access to our private Discord server.https://www.patreon.com/thepowersweepSubscribe to The Power Sweep's Substack to stay in touch and get content beamed straight to your email inboxhttps://thepowersweep.substack.com/Buy a T-Shirt or Sweatshirt - Look good while supporting The Power Sweep.https://www.teepublic.com/stores/the-power-sweep?ref_id=25927Leave us a 5-Star Review on iTunes - It helps more people find the show!Support this show http://supporter.acast.com/blue-58.

June 17, 2025 - Buffalo, Albany, and Syracuse are all poised for a change in leadership, with the next mayors likely coming from the winner of the Democratic primaries. We talk about some of the unifying themes of these races with Alex Elmasri, a vice president with The Parkside Group.

More taxes on sports gambling could be coming to one southern state to help support local college athletics. Correspondent Gethin Coolbaugh reports.

Welcome to The Perfect Place to Put a Practice! In this episode, host Mike Green from Doctor Demographics reveals 5 key signs a midsize market is about to rapidly grow—perfect for healthcare professionals looking to open or expand their practice.

The Mariners are set up to make big changes at the deadline, but will they pull the trigger, and what teams would they trade with? Bump and Stacy discuss who the M’s should target in a trade and listen to some comments from Aaron Goldsmith on the current state of the team. Bump talks about the Shemar Stewart hold-out situation, the Seahawks WR room, coaches on the hot seat, and more in Four Down Territory. They discuss, “who was in the wrong?” when it comes to the Rafael Devers trade, Davey Martinez situation, and Shemar Stewart negotiations. And they wrap up the show by telling you what you Need To Know.

Scott Bauer says the move in oil “doesn't make any sense to me,” because there's only been “continued escalation” in the Middle East. He thinks it's a “buy the dip” – but “only until this situation has been resolved.” After the resolution, he expects a big sell-off. On Bitcoin, he notes volatility is ticking up, which he says tends to be a precursor to “a very big move.”======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

In this episode of The President's Daily Brief: Mounting evidence suggests Israel may be preparing to launch a military strike on Iran. The Israeli military releases documents it says prove Hamas has been systematically confiscating humanitarian aid in Gaza. A U.S.-backed aid group accuses Hamas of killing multiple workers in a targeted attack. And in today's Back of the Brief: tragedy in India, where an Air India flight crashes just after takeoff, killing 244—though one passenger is reportedly alive. To listen to the show ad-free, become a premium member of The President's Daily Brief by visiting PDBPremium.com Please remember to subscribe if you enjoyed this episode of The President's Daily Brief. YouTube: youtube.com/@presidentsdailybrief TriTails Premium Beef: Visit https://TryBeef.com/PDB & Spend $399+ at TriTails by June 15 and get 2 lbs of ground beef free—plus, from June 13–15, buy a gift card for Dad and get a 10% bonus card for yourself! StopBox: Get firearm security redesigned and save with BOGO the StopBox Pro AND 10% OFF @StopBoxUSA with code PDB at https://stopboxusa.com/PDB! #stopboxpod Learn more about your ad choices. Visit megaphone.fm/adchoices

These players may have had a rough 2024 season, but they're poised for a huge rebound in 2025 - take advantage of their average draft position!    watch on YouTube -> https://youtu.be/Ar-x9oXPwLQ 

Housing analyst Melody Wright sees prices headed downwards nationally this year as inventory continues to explode higher in more and more markets.WORRIED ABOUT THE MARKET? SCHEDULE YOUR FREE PORTFOLIO REVIEW with Thoughtful Money's endorsed financial advisors at https://www.thoughtfulmoney.com#homeprices #housingmarket #mortgagerates _____________________________________________ Thoughtful Money LLC is a Registered Investment Advisor Promoter.We produce educational content geared for the individual investor. It's important to note that this content is NOT investment advice, individual or otherwise, nor should be construed as such.We recommend that most investors, especially if inexperienced, should consider benefiting from the direction and guidance of a qualified financial advisor registered with the U.S. Securities and Exchange Commission (SEC) or state securities regulators who can develop & implement a personalized financial plan based on a customer's unique goals, needs & risk tolerance.IMPORTANT NOTE: There are risks associated with investing in securities.Investing in stocks, bonds, exchange traded funds, mutual funds, money market funds, and other types of securities involve risk of loss. Loss of principal is possible. Some high risk investments may use leverage, which will accentuate gains & losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods.A security's or a firm's past investment performance is not a guarantee or predictor of future investment performance.Thoughtful Money and the Thoughtful Money logo are trademarks of Thoughtful Money LLC.Copyright © 2025 Thoughtful Money LLC. All rights reserved.

A potentially historic military operation is unfolding as CBS reports Israel is fully prepared to launch a strike on Iran. With uranium enrichment violations confirmed by the IAEA and fears of nuclear material reaching terror groups like Hamas and the Houthis, the U.S. has begun evacuating non-essential personnel from the Middle East. This explosive broadcast connects the dots between Iran's nuclear deceit, Chinese drone support, and weak U.S. deterrence, arguing that failure to act decisively could bring nuclear terrorism to American shores. As Israel takes the lead, questions loom: Will the U.S. support the mission? Can Iran be stopped before the world faces a nuclear nightmare?

Jonathan Agnew is joined by Sir Alastair Cook, Firdose Moonda and Jim Maxwell after the second day of the World Test Championship Final at Lord's. 14 wickets fell for the second day in a row to leave the contest in the balance. We hear from Australia pace bowler Mitchell Starc as well as South African bowler Lungi Ngidi.

In this episode of Poised for Exit, we're joined by Muthu Periakaruppan, CPA and President of MP Sales Tax, to dive into a topic that's often overlooked but critical when preparing to sell a business: sales and use tax.Muthu explains how many business owners, especially in industries like manufacturing, life sciences, and trucking, unknowingly overpay sales tax and may be eligible for sizable refunds. He walks us through how his firm helps recover those funds and ensures clients are in compliance before a sale. We cover key issues like multi-state nexus, exemption certificates, voluntary disclosures, and how these all impact the value of a business during an exit.We also dive into the topic of AI, as Muthu shares how it is transforming invoice review, helping his team flag potential refund opportunities faster and focus on strategy instead of routine tasks. With a background as a former state auditor and years of experience advising privately held companies, he brings a sharp perspective on how to protect business value and avoid tax surprises during due diligence.If you're interested in learning how to avoid costly tax mistakes, this conversation is a must-listen!Connect with Muthu here or email: muthu@mpsalestax.comConnect with Julie Keyes, Keyestrategies LLCFounder, Consultant, Author, Pod-caster and Instructor

Watch clips on YouTube! Subscribe to the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SPEAK YOUTUBE CHANNEL⁠⁠⁠ (00:00) First impressions of Aaron Rodgers on Steelers (16:20) Was Tyrese Haliburton crowned as a superstar too early? (34:41) Which 2nd year QB makes the biggest jump this year? / Terry McLaurin is holding out (45:37) Key's Big List (51:15) Should Jason Kidd want to leave the Mavs for the Knicks HC job? / Knicks best team for Kevin Durant? (1:08:59) Can Aaron Rodgers add to his NFL legacy this season? / Smart for Vikings to choose J.J. McCarthy over Rodgers? (1:23:52) Mistake for Giannis Antetokounmpo to stay with Bucks? (1:29:04) Final thoughts Learn more about your ad choices. Visit podcastchoices.com/adchoices

Packers Total Access Hour 2 : Pass Rush Deep Dive & Is Lukas Van Ness Poised For A Breakout Year? 

Packers Total Access Hour 2 : Pass Rush Deep Dive & Is Lukas Van Ness Poised For A Breakout Year?